Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study. Although DLB is the second most common neurodegenerative dementia following Alzheimer's ...
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...